98%
921
2 minutes
20
In intervention studies, alcohol consumption is often measured by self-report alone, which can be impacted by social desirability, recall, and other biases. Biomarkers and biosensors have gained popularity as objective measurements of alcohol consumption that can improve the accuracy of results. This scoping review provides a narrative overview and describes the use of biomarkers in alcohol intervention studies to inform future research. We conducted a review of alcohol intervention literature including published studies and Clinicaltrials.gov registrations (2000-2021). Randomized controlled trials, quasi-experimental, and nonexperimental studies were included if they piloted or evaluated an intervention aimed at reducing unhealthy alcohol consumption and if an alcohol biomarker was used. Data charting included type of biomarker(s), the country and context of the study location, and a description of how the biomarker was used in analysis. We identified 168 alcohol intervention studies that included at least one biomarker. Blood alcohol content was the most used (N = 76). There was an upward trend in biomarker use over time; 24% of studies were published between 2000 and 2010, and 76% between 2011 and 2021. The use of direct biomarkers, phosphatidylethanol and ethyl glucuronide, and biosensors has increased in frequency over time relative to indirect biomarkers, such as aspartate aminotransferase, carbohydrate-deficient transferrin, and alanine aminotransferase. Most studies were conducted in high-income countries; only 15% were conducted in a low- or middle-income country. More than half of completed studies did not report on comparisons between self-report and biomarker results even when both were collected. Among studies that did report a comparison, 26% reported discordance between self-report and biomarker results. The use of direct biomarkers and biosensors is accelerating. There is a need for more consistency in reporting biomarker/self-report concordance results, more comparisons between multiple biomarkers, and for greater geographic representation within the alcohol biomarker literature.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/acer.70114 | DOI Listing |
Brain Behav
September 2025
Key Laboratory of Endocrine Glucose & Lipids Metabolism and Brain Aging, Ministry of Education; Department of Radiology, Shandong Provincial Hospital, Affiliated to Shandong First Medical University, Jinan, Shandong Province, China.
Background: The susceptibility values of the basal ganglia reflect the health status of these nuclei. We aimed to explore the associations between various demographic characteristics, lifestyle factors, and biological factors that have the potential to contribute to magnetic susceptibility and investigate the comprehensive impact of these multiple factors on basal ganglia susceptibility values.
Methods: We included 25,980 participants from the UK Biobank.
J Diabetes
September 2025
Division of Nephrology, Kidney Research Institute, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
Aims: Diabetes is a global public health crisis, especially when it is accompanied by microvascular complications such as diabetic kidney disease (DKD). The purpose of this study was to explore the relationship between the combined lifestyle factors of diabetes patients and their joint effects with genetic risk and the risk of DKD.
Materials And Methods: We included individuals diagnosed with diabetes at baseline from UK Biobank.
Brain Behav
September 2025
Department of Dermatology, Yulin First Hospital, Yulin, Shaanxi Province, China.
Background: Psoriasis is linked with an elevated risk of anxiety disorders, and there may be a temporal relationship between the two. However, the association between anxiety status and its duration with psoriasis is unclear.
Objectives: The present work aimed to figure out the association between anxiety and the risk of psoriasis.
Mol Psychiatry
September 2025
Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur St., Warsaw, 02-093, Poland.
Alcohol use disorder (AUD) is characterized by pathological motivation to consume alcohol and cognitive inflexibility, leading to excessive alcohol seeking and use. In this study, we investigated the molecular correlates of impaired extinction of alcohol seeking during forced abstinence using a mouse model of AUD in the automated IntelliCage social system. This model distinguished AUD-prone and AUD-resistant animals based on the presence of ≥2 or <2 criteria of AUD, respectively.
View Article and Find Full Text PDFMol Psychiatry
September 2025
Section on Clinical Genomics and Experimental Therapeutics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
Pharmacological modulation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) through dual GIP/GLP-1 receptor agonists, commonly used for diabetes and obesity, shows promise in reducing alcohol consumption. We applied drug-target Mendelian randomization (MR) using genetic variation at these loci to assess their long-term effects on problematic alcohol use (PAU), binge drinking, alcohol misuse classifications, liver health, and other substance use behaviors. Genetic proxies for lowered BMI, modeling the appetite-suppressing and weight-reducing effects of variants in both the GIPR and GLP1R loci ("GIPR/GLP1R"), were linked with reduced binge drinking in the primary (β = -0.
View Article and Find Full Text PDF